Abstract
Introduction
Recombinant adeno-associated virus vectors, derived from a dependent human parvovirus, can transduce non-dividing normal cells to yield long-term transgene expression associated with a minimal immunological response 1, 2 . Among these vectors, a recombinant adeno-associated virus serotype 2 vector (rAAV2) is capable of transducing neural cells, making it an important potential vector for delivery of therapeutic genes into neural cells for treatment of CNS disease [3] [4] [5] . However, the transduction efficiency (TE) of rAAV2 in neural cells is not optimal for most therapeutic needs (Monahan and Samulski, 2000) , at least in part because the singlestranded viral DNA must be converted to a double-stranded form prior to transgene expression 6, 7 . Several studies have demonstrated that rAAV2 is better able to transduce cells that have proliferation potential; for example, rAAV2 showed a 200-fold difference in transducing S-phase cells versus non-S-phase cells 8, 9 . Thus, researchers have sought to identify chemicals capable of modulating the transduction environment inside rAAVinfected cells at non-cytotoxic levels. Two DNA synthesis inhibitors, hydroxyurea (HU) and aphidicolin (Aphi), were shown to dramatically increase the transduction efficiency of rAAV in a stationary culture 8, and tyrphostin-1 (Tyr-1), an EGFR tyrosine kinase inhibitor, was shown to act as an extremely strong stimulator of rAAV transduction in multiple cell types 10 . Recently, we showed that co-treatment with HU and Tyr-1 dramatically increased the transduction efficiency of rAAV2 in human cancer cells of different origins 11 . Here, we investigated whether these same chemical co-treatments could enhance rAAV2 transduction efficiency in primary cortical neural cells.
Methods
Cell culture and virus preparation. 293T and SK-Hep1 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, L-glutamine (2 mM), penicillin (100 IU/ml) and streptomycin (50 µg/ml), in a 5% CO 2 incubator at 37 ºC. Primary cultures of mouse cortical neurons from 16 day-old Balb/c mouse embryos were prepared and maintained as described previously 20 . Plasmid rAAV2-GFP, consisting of a GFP gene expression cassette embedded in the 5'-and 3'-terminal repeat sequences (TRs) of human AAV2 was generated with an AAV helperfree system (Stratagene, WA, USA). Briefly, 293T cells were transfected with by the calcium phosphate method 21 in a 1:1:1 molar ratio. The virus was purified from cells and media harvested 2 days post-transfection, as described previously 22 . The number of total rAAV2 particles in each preparation was estimated by ELISA (Progen Inc. Heigelberg, Germany).
Light and fluorescence microscopy
At various time points, cells were examined under a light microscope (LM) or a fluorescent microscope (FM) at 100-200 X magnification. Pictures were taken using a digital camera, and images were adjusted using the Adobe program to yield identical conditions for each experiment.
Cell cycle analysis. The change in DNA content was estimated by DNA staining with propidium iodide (PI). About 1-5 x 10 5 cells resuspended in PBS were treated with ice-cold 70% EtOH. After centrifugation, the cells were incubated in PBS with 0.1 mg/ml of RNase and 40 µg/ml of PI solution for 30 min at 37ºC. Flow cytometric analysis was carried out using a FACSCalibur flow cytometer (Becton Dickinson) and the DNA content was analyzed with the ModFit LT2.0 and Cellquest software packages.
Immunoblotting analysis and immunocytochemistry
For the immunoblotting analysis, 1 x 10 5 cells were lysed. The lysate was pre-cleared and resolved by 10% reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were immunoblotted using PVDF membrane and analyzed with 1-5 µg of primary antibody specifically recognizing pp38 (Cell Signaling Technology, MA, USA) or actin (Sigma, MO, USA). Bands were visualized by ECL analysis. For immunocytochemistry, cells were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 1 h or absolute methanol for 30 min (Ki-67, Sigma), respectively. Each sample was then treated with a blocking solution containing 1% BSA and 0.1% TritonX100 in PBS, followed by the addition of the appropriate primary antibody (MAPII, Chemicon, Temecula, CA; GFAP, Chemicon; neurofilament; Sternberger) Finally, cells were treated with the appropriate Cy3-or FITC-conjugated secondary antibody and visualized under a fluorescence microscope.
Disscussion
Light microscopic analysis showed that the routinely prepared primary cortical neural cultures contained cells with the typical morphological properties of neurons, including oval-shaped cell bodies and numerous dendritic stretches (Fig.  ffigure1>1A) .
Immunocytochemical observations indicated that the cell cultures consisted of mostly neural cells with minor contaminating astrocytes (Fig. 1A , MAPII and GFAP pictures). Four days after plating, the astrocyte population comprised 1-3 % of the culture; the population increased by several fold by day 11 under culture conditions that did not favor astrocyte proliferation (data not shown). The pattern of transduction by rAAV2 was examined by infecting the cells with 10 3 -10 4 total rAAV2-GFP particles (Fig. 1B ) per cell (TP/cell) and immunocytostaining for either neurofilament (neuron marker) or GFAP (astrocyte marker). Our results showed that the GFP signal was weakly visible at 2-3 day post-infection (dpi) and could be readily observed at 7 dpi (Fig.  1C) . All GFP-expressing cells were neural cells, not astrocytes, in agreement with the previous reports 1, 3, 12 . We then examined the response of these cultures to cotreatment with chemicals previously reported to dramatically increase the transduction efficiency (TE) of rAAV2 8, 10 . Our group and others have reported that Aphi or HU pretreatment and subsequent removal activates DNA polymerase and induces DNA synthesis 8, 11 . Under these conditions, stationary non-neural cells were able to reenter the cell cycle after G1/G0 arrest, resulting in a sudden surge of the S/G2/M phase population. Here, we evaluated whether the same phenomenon occurred in cultured cortical neural cells from 16 day-old mouse embryos, using cell cycle analysis with PI staining and immunocytochemistry for anti-Ki-67-positive nuclei. We found that most of the neural cells remained in G1/G0 stage (94.5 ± 1.6 %) on days 3 and 7 following Aphi or HU pretreatment ( Fig. 2A, B) . Consistent with the previous report 11, human hepatocellular carcinoma SK-Hep1 cells experienced a drastic increase in TE under these conditions, indicating that they had effectively escaped from G1/G0 arrest. The Ki-67 staining analysis revealed that only a low percentage of nuclei stained positively after HU pretreatment (Fig. 2C) , and double-staining with GFAP indicated that the Ki-67 positive cells were astrocytes. Similar Ki-67 staining results were observed following Aphi pretreatment (data not shown).
Fig 2:
Primary cortical neural cells isolated from 16 day-old mouse embryos were mostly in G1/G0 stage. Cells were chemically treated for 16 h, chemicals were removed, and cultures were further incubated for 3 days for neural cells, or 1 (1D) or 5 (5D) days for SK-Hep1 cells prior to PI staining. Cell cycle profiles were analyzed by flow cytometry (A, B) . Neural cell cultures were pretreated with HU, the agent was removed and cells were incubated for 3 days prior to double immunostaining for Ki-67 and either MAP II or GFAP (C). MT, mocktreated; 14D or 16D, neural cell cultures derived from 14 or 16 day-old embryonic mouse cortices; Ki-67, FITCconjugated anti-Ki-67 antibody; MAP II; Cy3-conjugated MAP II antibody; Merge, neural cells stained for both Ki-67 and MAP II; Astrocyte; astrocytes stained positive for both Ki-67 and GFAP. The data indicate that pretreatment with the genotoxic agents did not affect the cell cycle in the tested neural cell cultures.
Previous studies have shown that Tyr-1 can enhance the TE of rAAV2 by enhancing conversion of the rAAV genome from single-stranded to double-stranded 10 . Tyr-1 can also increase transcriptional level of linear vector DNA templates by stimulating the activity of JNK and p38, as shown by increased phosphorylation of p38 13 . Accordingly, we next examined whether p38 was phosphorylated in neural cells after Tyr-1 treatment. Our data indicated that unlike SK-Hep1 cells, neural cells did not show any change in p38 phosphorylation status following treatment with Tyr-1 (Fig. 3) .
Fig 3:
Tyrphostin-1 treatment did not induce phosphorylation of p38 in the cultured neural cells. Immediately after Tyr-1 treatment, the p38 phosphorylation status was examined by Western blotting with an anti-phospho p38 antibody. Anti-actin was used as the loading control. The results indicate that p38 was not phosphorylated in neural cells in the absence (-) or presence (+) of Tyr-1.
Finally, we tested the enhancing effect on TE by pretreatment of the chemicals. The relative TE measured on 7 dpi indicated that the co-treatments had no positive effect on the neural cultures (Fig. 4) . The chemical treatments did not induce any cytopathic effects in the neural cells as tested by MTT and LDH cell viability assays (data not shown), indicating that this ineffectiveness was not associated with cytotoxicity . One of the critical issues for the practical usefulness of rAAV2 is its ability to direct sufficient transgene delivery to the proper target 14 . Our results showed that the transduction ability of simple rAAV2 infection in primary neural cells is quite poor (0.06 ± 0.02 % with 5 x 10 3 TP/cell). This poor efficiency can be improved somewhat by co-infecting cells with wildtype adenovirus 5 (data not shown) 15,16, but this strategy is impractical, as target cells are eventually killed by adenovirusinduced cytopathic effects. Nevertheless, this property suggests that rAAV2 effectively enters primary cortical neural cells through virus-receptor interaction, but fails to express the transgene owing to other rate-limiting step(s) 7, 14 . Previous studies have identified several chemicals capable of enhancing the rAAV2 TE by in various cell types, without attendant cytotoxicity 8, 10, 17 . However, our results show that, unlike the case in the previously tested cell types, neither DNA synthesis blockers (HU or Aphi) at low concentration nor EGFR tyrosine kinase inhibitor (Tyr-1) enhanced the TE in primary cortical neural cells of 16-day old mouse embryos. In non-neural cells, HU or Aphi pretreatment and subsequent removal leads to temporary synchronization at G1/G0, followed by synthesis of DNA polymerase and entry of cells into S phase, leading to efficient rAAV transduction 8, 11 . In contrast, nearly 95% of the cortical neural cells in our cultures were already in G1/G0 stage, and no alteration in cell cycle was observed following treatment with the tested agents. Furthermore, the 16 day-old cortical neural cells did not show stimulation of p38 activity in the presence of Tyr-1, which may explain why Tyr-1 treatment had no positive effect on the TE. Together, these data indicate that the tested cortical neural cells may be locked in G0 stage and are unable to induce DNA polymerase synthesis. Thus, Hu, Aphi or Tyr-1 may only improve rAAV transduction in cells that retain their proliferation potential.
In sum, we herein showed that pretreatment of DNA synthesis and/or EGFR tyrosine kinase inhibitor does not enhance rAAV-mediated gene expression of 16-old cortical neural cells. When we examined cortical neural cells at an earlier stage (from 14 day-old mouse embryos), we detected around 11% of cells in S phase, as compared to only 4% in 16 dayold cells (Fig. 3A, 14D ). This may suggest that a higher rAAV2 TE (with or without chemicals) could be achieved in cortical neural cells taken from an earlier stage of development. Recently, two groups reported the development of a selfcomplementary rAAV2 (scAAV2), which bypasses the host cell-mediated synthesis of the double-stranded rAAV genome from the single-stranded version, and consequently does not require target cells to have proliferating potential 18, 19 . This new strategy may be useful for effective transduction of non-proliferating cortical neural cells at any stage, which possibility is under investigation.
